Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report sent to investors on Tuesday,RTT News reports. Wedbush currently has a $11.00 price objective on the stock.

CATX has been the subject of several other research reports. Scotiabank began coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday, March 31st. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Royal Bank of Canada dropped their price target on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, March 27th. Finally, Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $12.75.

Perspective Therapeutics Trading Up 1.6%

NYSE CATX opened at $2.55 on Tuesday. The firm has a 50-day simple moving average of $2.25 and a 200 day simple moving average of $3.84. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $19.05.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor acquired 22,026 shares of the company’s stock in a transaction dated Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares in the company, valued at approximately $133,017.92. This represents a 58.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert F. Williamson III acquired 38,145 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were purchased at an average cost of $2.14 per share, with a total value of $81,630.30. Following the acquisition, the director now owns 108,982 shares of the company’s stock, valued at approximately $233,221.48. This represents a 53.85% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 115,696 shares of company stock valued at $256,344. Corporate insiders own 3.72% of the company’s stock.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently modified their holdings of the company. HighTower Advisors LLC increased its holdings in shares of Perspective Therapeutics by 13.2% during the first quarter. HighTower Advisors LLC now owns 201,586 shares of the company’s stock worth $429,000 after buying an additional 23,475 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Perspective Therapeutics in the first quarter valued at approximately $2,647,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Perspective Therapeutics by 6.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 434,085 shares of the company’s stock valued at $925,000 after purchasing an additional 27,119 shares in the last quarter. Citizens Financial Group Inc. RI increased its holdings in shares of Perspective Therapeutics by 100.0% in the first quarter. Citizens Financial Group Inc. RI now owns 100,000 shares of the company’s stock valued at $213,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new stake in shares of Perspective Therapeutics in the first quarter valued at approximately $288,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.